Aimei Health Technology Co., Ltd (AFJK) Financial Ratios
3 years of historical data (2023–2025) · Financial Services · Shell Companies
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
21.48
↑+28% vs avg
5yr avg: 16.78
30Y Low1.3·High32.2
ROE
↑
2.6%
↓+22% vs avg
5yr avg: 2.2%
30Y Low0%·High4%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
AFJK Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Aimei Health Technology Co., Ltd trades at 251.0x earnings, 21% above its 5-year average of 207.4x, sitting at the 100th percentile of its historical range. Compared to the Financial Services sector median P/E of 13.1x, the stock trades at a premium of 1810%.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Market Cap | $261M | $259M | $97M | — |
| Enterprise Value | $263M | $261M | $97M | — |
| P/E Ratio → | 251.03 | 376.53 | 38.21 | — |
| P/S Ratio | — | — | — | — |
| P/B Ratio | 21.48 | 32.22 | 1.34 | — |
| P/FCF | — | — | — | — |
| P/OCF | — | — | — | — |
P/E links to full P/E history page with 30-year chart
AFJK EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| EV / Revenue | — | — | — | — |
| EV / EBITDA | — | — | — | — |
| EV / EBIT | — | — | — | — |
| EV / FCF | — | — | — | — |
AFJK Profitability
Margins and return-on-capital ratios measuring operating efficiency
ROE of 2.6% is modest, trailing the sector median of 9.4%.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Gross Margin | — | — | — | — |
| Operating Margin | — | — | — | — |
| Net Profit Margin | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| ROE | 2.6% | 2.6% | 3.6% | 0.2% |
| ROA | 2.5% | 2.5% | 3.5% | 0.2% |
| ROIC | -1.5% | -1.5% | -1.1% | — |
| ROCE | -2.0% | -2.0% | -1.5% | -0.0% |
AFJK Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $2M ($2M total debt minus $2929 cash).
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Debt / Equity | 0.25 | 0.25 | 0.00 | — |
| Debt / EBITDA | — | — | — | — |
| Net Debt / Equity | — | 0.25 | 0.00 | -0.01 |
| Net Debt / EBITDA | — | — | — | -3.39 |
| Debt / FCF | — | — | — | — |
| Interest Coverage | — | — | — | — |
AFJK Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
The current ratio of 0.00x is below 1.0, meaning current liabilities exceed current assets. The current ratio has declined from 23.38x to 0.00x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Current Ratio | 0.00 | 0.00 | 0.04 | 23.38 |
| Quick Ratio | 0.00 | 0.00 | 0.04 | 23.38 |
| Cash Ratio | 0.00 | 0.00 | 0.03 | 23.38 |
| Asset Turnover | — | — | — | — |
| Inventory Turnover | — | — | — | — |
| Days Sales Outstanding | — | — | — | — |
AFJK Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Aimei Health Technology Co., Ltd does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business. The earnings yield of 0.4% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Dividend Yield | — | — | — | — |
| Payout Ratio | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Earnings Yield | 0.4% | 0.3% | 2.6% | — |
| FCF Yield | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | — |
| Shares Outstanding | — | $4M | $9M | $9M |
Peer Comparison
Compare AFJK with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 AFJKYou | $261M | 251.0 | — | — | — | — | 2.6% | -1.5% | — |
 CANG | $250M | 5.7 | 3.1 | — | 55.3% | 22.2% | 7.6% | 4.6% | 0.9 |
 BTBT | $589M | 9.2 | 8.5 | — | 61.9% | 16.8% | 9.2% | 6.5% | 0.2 |
 CLOV | $1B | -16.6 | — | — | 18.5% | -4.4% | -26.3% | -34.0% | — |
 ACMR | $4B | 43.2 | 27.5 | — | 44.4% | 12.1% | 6.2% | 7.0% | 2.4 |
 GDRX | $973M | 33.3 | 4.0 | 5.9 | 82.1% | 13.4% | 4.5% | 13.0% | 0.3 |
 HIMS | $7B | 50.3 | 42.7 | 89.6 | 59.3% | 5.2% | 25.2% | 10.7% | 6.4 |
 TDOC | $1B | -6.1 | 15.1 | 4.4 | 69.5% | -10.4% | -13.9% | -11.5% | 10.4 |
 AMWL | $129M | -1.3 | — | — | 53.3% | -42.2% | -33.9% | -95.1% | — |
 DOCS | $5B | 23.5 | 21.1 | 19.6 | 90.2% | 39.9% | 22.5% | 20.0% | 0.1 |
 PHVS | $2B | -10.2 | — | — | — | — | -41.2% | — | — |
| Financial Services Median | — | 13.1 | 11.5 | 10.6 | 63.6% | 21.6% | 9.4% | 5.7% | 4.1 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 3 years · Updated daily
See AFJK's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs AFJK Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare AFJK vs CANG
Side-by-side business, growth, and profitability comparison vs Cango Inc..
Start ComparisonAFJK — Frequently Asked Questions
Quick answers to the most common questions about buying AFJK stock.
What is Aimei Health Technology Co., Ltd's P/E ratio?
Aimei Health Technology Co., Ltd's current P/E ratio is 251.0x. The historical average is 38.2x. This places it at the 100th percentile of its historical range.
What is Aimei Health Technology Co., Ltd's ROE?
Aimei Health Technology Co., Ltd's return on equity (ROE) is 2.6%. The historical average is 2.2%.
Is AFJK stock overvalued?
Based on historical data, Aimei Health Technology Co., Ltd is trading at a P/E of 251.0x. This is at the 100th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.